Clinical significance and diagnostic value of serum NSE, CEA, CA19‑9, CA125 and CA242 levels in colorectal cancer
Hai Luo, Kexin Shen, Bo Li, Ruiqi Li, Zeming Wang, Zhongshi Xie
Abstract
The present study investigated the value of combinations of five specific tumor biomarkers for the diagnosis of colorectal cancer (CRC): Neuron‑specific enolase (NSE), carcinoembryonic antigen (CEA), cancer antigen (CA)19‑9, CA125 and CA242. Associations between these markers and clinicopathological characteristics (including the Tumor‑Node‑Metastasis stage) were also assessed. Serum levels of the 5 markers were compared between 358 patients with CRC and 298 healthy individuals (CRC and control group, respectively). The NSE concentration of the CRC group was significantly higher compared with the control. Furthermore, patients at clinical stage III+IV exhibited significantly higher NSE levels compared with those at stage I+II. The serum NSE level of N+ patients was significantly higher compared with the N‑ group, and the NSE level of M1 patients was significantly compared with the M0 group. NSE level was also significantly associated with tumor stage, lymph node metastasis, distant metastasis and hematochezia. The area under the receiver operating characteristic curve (AUC) for NSE in CRC was 0.766, which was significantly higher than that of the other four markers, which ranged from 0.560‑0.682. The AUC of NSE, CEA, CA19‑9, CA125, CA242 combined was significantly higher compared with any of the markers individually (range, 0.796‑0.858). Therefore, serum NSE may be a good clinical tool for the auxiliary diagnosis of colorectal cancer. Besides, the combination of NSE, CEA, CA19‑9, CA125 and CA242 was significantly more sensitive compared with NSE alone. Thus, the combined detection of the 5 tumor markers may be more useful for the diagnosis of CRC.